Anew Labs

Embodied AI & Robotics

First roundUSD 290M2026-09-16View funding history →

Valuation: USD 1.5B (as of 2026-09)
Total funding: USD 290M
Data cutoff: 2026-09-18

Company Profile

Spun off from ByteDance's internal AI-for-Science drug discovery team in June 2026, Anew Labs integrates AI with experimental science for new drug development. ByteDance retains a 56% controlling stake. The company possesses one of the most complete technical closed loops among major Chinese tech firms' AI pharmaceutical initiatives.

Founded: 2026
Headquarters: Shanghai, China